Business
vTv Therapeutics to Present Additional Positive Clinical Study Results from Phase 2 Simplici-T1 Study of TTP399 as Adjunctive Therapy for Patients with Type 1 Diabetes at EASD Virtual Meeting
Potential First-in-Class, Liver-Selective Glucokinase Activator HIGH POINT, N.C., Sept. 16, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT)
About this update from Vtv Therapeutics Inc.
[{"type":"text","content":"Potential First-in-Class, Liver-Selective Glucokinase Activator\nHIGH POINT, N.C., Sept. 16, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced it will deliver two oral presentations emphasizing the potential of TTP399 as an oral adjunctive therapy in type 1 diabetes at the 56th Annual Meeting of the European Association for the Study of Diabetes, held virtually September 21-25, 2020.\n In June 2020 at the American Diabetes Association’s 80th Virtual Scientific Sessions, the Company presented positive clinical data from the Phase 2 Simplici-T1 Study confirming that treatment with TTP399 resulted in significant improvements in HbA1c, with reduction in bolus insulin dose, without increasing the risk of hypoglycemia or diabetic ketoacidosis (DKA). Details of the EASD virtual presentations follow: Oral Presentation Title: “The Simplici-T1 Trial: Activation of Glucokinase by TTP399 Improves Glycaemic Control in Patients with Type 1 Diabetes”Presentation Number: 50 Category: OP 09 Novel Agents in Type 1 DiabetesDate and Time: Tuesday, September 22, 2020, 8:45 AM - 9:00 AM ET Oral Presentation Title: “Mechanism Matter: Preliminary Evidence That Activation of Glucokinase by TTP399 Does Not Increase Plasma or Urine Ketones in Type 1 Diabetes” Presentation Number: 51Category: OP 09 Novel Agents in Type 1 Diabetes Date and Time: Tuesday, September 22, 2020, 9:00 AM - 9:15 AM ET About the Simplici-T1 StudySimplici-T1 was a multi-center, randomized, double-blind, adaptive study assessing the safety and efficacy of TTP399 as an adjunct to insulin therapy in adults with T1D. The primary endpoint was the change in HbA1c at week 12. The study was conducted with support from JDRF, the leading global organization funding research in type 1 diabetes. This Phase 2 learn-and-confirm study was conducted in two parts under a treat-to-target protocol to evaluate the safety and efficacy of TTP399 in T1D patients over 12 weeks of daily dosing following a multi-week insulin optimization and placebo run-in period. Part 1 enrolled 19 patients on both insulin pumps and CGMs. The positive topline results from the learning phase - Part 1 were reported in June 2019. The confirming phase, Part 2, enrolled 85 patients that used either insulin pumps or multiple daily injections of insulin; CGMs were allowed for those patients using the de...